e-Therapeutics plc engages in the discovery and development of drugs through its proprietary platform in network pharmacology and chemical biology. It focuses on the discovery of drugs for cancer and neurodegeneration. The company’s drug candidates include ETS2101, which is in Phase Ib clinical trial for the treatment of hepatocellular and pancreatic cancer; and ETS6103, a Phase IIb trial product for depressive disorders. It also develops ETX1153c, a resistance-less antibiotic; ETS2300 for telomerase inhibition in anti-cancer; ETS3100, a small molecule anti-TNFa; and ETS2400 for Hedgehog pathway inhibition. The company was founded in 2001 and is based in Long Hanborough, the United Kingdom.
e-therapeutics plc (ETX:London)
17 Blenheim Office Park
Long Hanborough, OX29 8LN
Phone: 44 1993 880 000
Fax: 44 1993 880 207www.etherapeutics.co.uk
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for ETX.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact E-THERAPEUTICS PLC, please visit www.etherapeutics.co.uk. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.